Akero Therapeutics — Technical Presentation (June 2020)
21 slides from Akero Therapeutics's technical presentation, Jun 30, 2020
Slide 1: A Global Disease, A Pioneering Treatment: BALANCED Study Readout
A Global Disease, A Pioneering Treatment BALANCED Study Readout Akero Therapeutics, Inc. June 30, 2020
Slide 2: Safe Harbor
- CONFIDENTIAL - SAFE HARBOR This presentation has been prepared by Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) and is made for in formational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sal
Slide 3: Introducing Efruxifermin
- CONFIDENTIAL - 3 INTRODUCING EFRUXIFERMIN Efruxifermin (EFX) ē - FRUX - i - FER - min (Formerly AKR - 001)
Slide 4: Substantial Histologic Improvements After Only 16 Weeks
- CONFIDENTIAL - Histological Improvements Safety & Tolerability SUBSTANTIAL HISTOLOGIC IMPROVEMENTS AFTER ONLY 16 WEEKS 4 • Response rates for all EFX treated subjects who achieved at least a 30% liver fat reduction and had end - of - treatment biopsies (N=40): • 48% NASH resolution without worseni
Slide 5: BALANCED Study Trial Design
- CONFIDENTIAL - 5 BALANCED STUDY TRIAL DESIGN MRI - PDFF Liver Biopsy Screening Randomization EFX 70mg (n=20) QW SC Injection EFX 50mg (n=20) QW SC Injection EFX 28mg (n=20) QW SC Injection Placebo (n=20) QW SC Injection Safety Follow - Up Liver Biopsies for Responders Week 6 Week 12 Screening Post
Slide 6: Baseline Demographics
- CONFIDENTIAL - BASELINE DEMOGRAPHICS Parameter Mean Placebo (N=21) EFX 28mg (N=19) EFX 50mg (N=20) EFX 70mg (N=20) Age (Years) 52 50 53 53 Sex (Male/Female) 6/15 9/10 10/10 9/11 Weight (kg) 99.6 108.2 103.6 103.1 BMI (kg/m 2 ) 37.6 38.8 36.7 37.2 Liver Fat Content (% by MRI - PDFF) 19.3 21.4 18.3
Slide 7: Substantial Reductions in Liver Fat at Week 12 Across All Dose Groups
- CONFIDENTIAL - Response Rate 2 Proportion of subjects who had a Week 12 MRI - PDFF showing ≥30% relative reduction SUBSTANTIAL REDUCTIONS IN LIVER FAT AT WEEK 12 ACROSS ALL DOSE GROUPS 7 Placebo 28mg 50mg 70mg Mean Absolute Reduction in Liver Fat 1 Placebo 10% 28mg 100% 50mg 100% 70mg 100% *** p<0
Slide 8: Reduction in Hepatocyte Stress and Collagen Synthesis Across All Dose Groups
- CONFIDENTIAL - -60% -50% -40% -30% -20% -10% 0% 10% BL W1 W4 W8 W12 W16 W20 Placebo 28mg 50mg 70mg ALT Mean Change from Baseline (%) REDUCTION IN HEPATOCYTE STRESS AND COLLAGEN SYNTHESIS ACROSS ALL DOSE GROUPS 8 * p<0.05, ** p<0.01, *** p<0.001, versus placebo (statistical significance tested only
Slide 9: Consistent Improvement in Steatohepatitis
- CONFIDENTIAL - Mean NAS Reduction Change in NAS from Baseline after 16 weeks of dosing 0% 20% 40% 60% 80% 100% Overall 0% 20% 40% 60% 80% 100% Overall NAS Reduction ≥2 Points with no Worsening of Fibrosis 1,2 Placebo N=2 50% 1 * All EFX N=40 78% 31 28 mg N=13 77% 10 5 0mg N=13 77% 10 70mg N=14 79%
Slide 10: High Response Rates on NASH Resolution Across All Doses
- CONFIDENTIAL - HIGH RESPONSE RATES ON NASH RESOLUTION AFTER 16 WEEKS ACROSS ALL DOSES 10 Source Data: BAS 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning 2 Secondary and exploratory histological endpoints were not powered for statistical significance * A single place
Slide 11: High Rates of Fibrosis Improvement Across All Treated Patients
- CONFIDENTIAL - HIGH RATES OF FIBROSIS IMPROVEMENT AFTER 16 WEEKS ACROSS ALL TREATED PATIENTS 11 Source Data: BAS 0% 10% 20% 30% 40% 50% 60% 70% Overall 0% 10% 20% 30% 40% 50% 60% 70% Overall Fibrosis Improvement ≥1 Stage with No Worsening of NAS 1,2 1 Improvement in liver fibrosis greater than or
Slide 12: Encouraging Response Rates for Both Fibrosis Improvement and NASH Resolution
- CONFIDENTIAL - 0% 10% 20% 30% 40% 50% 60% 70% Overall 0% 10% 20% 30% 40% 50% 60% 70% Overall ENCOURAGING RESPONSE RATES FOR BOTH FIBROSIS IMPROVEMENT AND NASH RESOLUTION AFTER 16 WEEKS 12 1 Subjects who achieve a NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning AND Impr
Slide 13: Safety Overview
- CONFIDENTIAL - SAFETY OVERVIEW Source Data: SS 13 Treatment - Emergent Adverse Event (TEAE) Classification Placebo (N=21) EFX 28mg (N=19) EFX 50mg (N=19) EFX 70mg (N=20) TEAE Leading to Death 0 0 0 0 TEAE Leading to Discontinuation 1 a 2 b 0 4 c Serious Adverse Event (SAE) 0 1 d 0 1 a Muscular Wea
Slide 14: Drug-Related Treatment-Emergent Adverse Events
- CONFIDENTIAL - DRUG - RELATED TREATMENT - EMERGENT ADVERSE EVENTS (TEAE s) Most Common (>10%) Drug - Related AEs * Placebo (N=21) All EFX (N=58) EFX 28mg (N=19) EFX 50mg (N=19) EFX 70mg (N=20) Diarrhea 1 2 (10%) 21 (36%) 5 (26%) 10 (53%) 6 (30%) Nausea 0 (0%) 19 (33%) 6 (32%) 4 (21%) 9 (45%) Incre
Slide 15: Clinically Meaningful Improvements in Glycemic Control After 16 Weeks
- CONFIDENTIAL - -50 -25 0 25 50 W16 CLINICALLY MEANINGFUL IMPROVEMENTS IN GLYCEMIC CONTROL AFTER 16 WEEKS Source Data: FAS; ANCOVA LS Mean 15 -20 0 20 40 60 80 100 120 W16 Adiponectin Placebo 28mg 50mg 70mg *** *** *** -40 -30 -20 -10 0 10 20 30 W16 C - Peptide Placebo 28mg 50mg 70mg ** ** ** -0.5
Slide 16: Weight Losses Observed for All Dose Groups
- CONFIDENTIAL - -4 -3 -2 -1 0 W16 70mg * -4.0 -3.0 -2.0 -1.0 0.0 BL W1 W4 W8 W12 W16 Placebo 28mg 50mg 70mg Mean Change in Body Weight (kg) 16 WEIGHT LOSSES OBSERVED FOR ALL DOSE GROUPS: FIRST REPORT OF SIGNIFICANT WEIGHT LOSS FOR FGF21 CLASS * * Mean Change in Body Weight at Week 16 (kg) * p<0.05,
Slide 17: Improved Lipoprotein Profile for Cardiovascular Health
- CONFIDENTIAL - IMPROVED LIPOPROTEIN PROFILE FOR CARDIOVASCULAR HEALTH Source Data: FAS; ANCOVA LS Mean 17 -15 -11 -7 -3 1 5 W16 LDL Cholesterol + 1% Placebo 28mg 50mg 70mg * -50 -40 -30 -20 -10 0 10 20 W16 - 37% - 45% - 43% + 8% Placebo 28mg 50mg 70mg *** *** *** Triglycerides 0 10 20 30 40 W16 HD
Slide 18: Development Landscape: NASH Resolution
- CONFIDENTIAL - DEVELOPMENT LANDSCAPE: NASH RESOLUTION 18 Proportion of Subjects with Resolution of NASH without Worsening of Fibrosis 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (201 8) Note: These data are derived fr
Slide 19: Development Landscape: Fibrosis Improvement
- CONFIDENTIAL - DEVELOPMENT LANDSCAPE: FIBROSIS IMPROVEMENT 19 Proportion of Subjects with ≥1 Stage Improvement in Fibrosis without Worsening of NAS 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (201 8) All EFX 50mg Pbo
Slide 20: Efruxifermin: Unique Potential as a Foundational NASH Monotherapy
- CONFIDENTIAL - EFRUXIFERMIN: UNIQUE POTENTIAL AS A FOUNDATIONAL NASH MONOTHERAPY 20 x Unprecedented fibrosis improvement x Best - in - field reductions of liver fat • Confirmed by NASH resolution x Ameliorated dyslipidemia • No LDL cholesterol increase x Improved glycemic control x Weight loss at
Slide 21: A Global Disease, A Pioneering Treatment
A Global Disease, A Pioneering Treatment NASDAQ: AKRO
Akero Therapeutics — Technical Presentation (June 2020) on 6ix